PET Tau and Amyloid-β Burden in Mild Alzheimer’s Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers
Manuscript Number:
17-0129R1
Author(s):
Azadeh Firouzian, Roger N. Gunn, Robert Howard, Ivan Koychev, Jennifer Lawson, Simon Lovestone, Clare MacKay, Basil Ridha, Lynn Rochester, James B. Rowe, Barbara J. Sahakian, Alan Thomas, Giovanna Zamboni, Henrik Zetterberg, Dominic ffytche
Disclosures
Dominic ffytche
Nothing to Disclose
Azadeh Firouzian
Nothing to Disclose
Roger N. Gunn
Consulting Fees:
Consultant for Abbvie, Biogen and Cerveau
Robert Howard
Nothing to Disclose
Ivan Koychev
Nothing to Disclose
Jennifer Lawson
Nothing to Disclose
Simon Lovestone
Consulting Fees:
SomaLogic medical advisory board (unpaid)
Consultancy to OptumLabs, Eisai, J&J
Lecture Fees:
Eisai (to be claimed)
Patents/Royalties
Named as senior inventor on patents on biomarkers held by KCL and Proteome Sciences
Grants
Agency:
AstraZeneca
Dates:
2014-2019
Agency:
EFPIA companies via IMI
Dates:
2012-2020
Clare MacKay
Nothing to Disclose
Basil Ridha
Nothing to Disclose
Lynn Rochester
Nothing to Disclose
James B. Rowe
Consulting Fees:
Advisory board membership for Medical Research Council, Wellcome Trust and National Institute for Health Research; Consultancy for Asceneuron;